Form 425 - Prospectuses and communications, business combinations:
SEC Accession No. 0001628280-19-014775
Filing Date
2019-12-05
Accepted
2019-12-05 16:19:45
Documents
9

Document Format Files

Seq Description Document Type Size
1 8-K a8-ksigningofaevimergeragr.htm 425 70324
2 EXHIBIT 2.1 ex-21agreementandplanofmer.htm EX-2.1 468908
3 EXHIBIT 10.1 ex-101cvragreement_final.htm EX-10.1 132565
4 EXHIBIT 10.2 ex-102formofvotingagreemen.htm EX-10.2 190111
5 EXHIBIT 10.3 ex-103promissorynotexazlic.htm EX-10.3 39154
6 EXHIBIT 10.4 ex-104promissorynotexgener.htm EX-10.4 40664
7 EXHIBIT 10.5 ex-105armisticebackstopagr.htm EX-10.5 125426
8 EXHIBIT 99.1 ex-991cerecortoacquireaevi.htm EX-99.1 42109
9 cerecorlogoa37.jpg GRAPHIC 16081
  Complete submission text file 0001628280-19-014775.txt   1133299
Mailing Address 435 DEVON PARK DRIVE, SUITE 715 WAYNE PA 19087
Business Address 435 DEVON PARK DRIVE, SUITE 715 WAYNE PA 19087 610-254-4201
Aevi Genomic Medicine, Inc. (Subject) CIK: 0001138776 (see all company filings)

EIN.: 980217544 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 425 | Act: 34 | File No.: 001-35112 | Film No.: 191270609
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Cerecor Inc. (Filed by) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 425
SIC: 2834 Pharmaceutical Preparations